Red cell folate concentrations in patients with Crohn’s disease on parenteral nutrition

Masaya Tominaga, Mitsuo Iida, Kunihiko Aoyagi, Norio Kohrogi, Toshiyuki Matsui and Masatoshi Fujishima

Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Maidashi 3–1–1, Higashi-Ku, Fukuoka 812, Japan.

Summary: To examine changes in the folate concentrations in red cell during relatively long-term total parenteral nutrition (TPN), 10 Japanese patients with Crohn’s disease (7 males), the mean Crohn’s disease activity index on admission being 211, were given folic acid in a dose of 400 µg/day (AMA-FDA formulation) or 800 µg/day for 6–16 weeks (mean 10.5). The red cell folate concentrations were determined before TPN and once every week or 2–4 weeks thereafter. The folate concentrations were very low even after TPN with folic acid of 400 µg/day. In those given 800 µg of daily folic acid, the folate levels tended to increase, but did not reach the normal range. We propose that folic acid over 800 µg/day or a double dose of AMA-FDA formulation should be prescribed for Crohn’s disease treated with long-term TPN.

Introduction

There has been no established drug therapy for Crohn’s disease. Total parenteral nutrition (TPN) or elemental diet is a common and primary therapy for this disease, aimed at bowel rest.1–5 Most patients, however, are in a state of latent hypoalimentation before the therapy, because of extensive intestinal lesions or due to the lack of ingestion of nutrients. Therefore, various vitamin deficiencies, such as folic acid and vitamin D, can frequently occur in such patients.2

To establish the dose of vitamins required for TPN, the Food and Drug Administration (FDA) prepared a parenteral vitamin formulation for adults in 1979, based on recommendations of the Nutrition Advisory Group of the American Medical Association.6 However, blood concentrations of vitamins have rarely been investigated in patients treated with long-term TPN, using the AMA-FDA formulation.7 We examined serial changes in the folate concentrations in red cell during relatively long-term TPN in 10 patients with Crohn’s disease. Of these patients, seven were given the dose of folic acid recommended by AMA-FDA and the remaining three were treated with a double dose.

Materials and methods

Patients

Ten Japanese patients with Crohn’s disease (7 males) admitted to Kyushu University hospital between October 1984 and October 1987 were studied. The average age of the patients was 30 years (range 18–52). The diagnosis of Crohn’s disease was based on X-ray examination, endoscopy, and biopsy. The sites of lesions were evident in both the small and large intestines in 6 patients, only in the small intestine in 3, and in the large intestine in one. The period of illness ranged from 1 to 8 years (average 3.4 years). The mean Crohn’s disease activity index (CDAI)8 on admission was 211 (range 93 to 394). All patients had normal renal and liver function.

Intravenous solution

Each patient was forbidden to take anything by mouth and was given TPN of 1924 Cal/day. The composition of daily TPN during the maintenance period is shown in Table I. Additionally, an intravenous fat emulsion (INTRAFAT, 10%, 200–500 ml) was administered through a peripheral vein once a week in each case. Two patients received oral salicylazosulphapyridine (SASP, 3 g/day).
Table 1 Composition of average daily TPN intake

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Amount/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy</td>
<td>8042 kJ</td>
</tr>
<tr>
<td>Nitrogen</td>
<td>91 g</td>
</tr>
<tr>
<td>Sodium</td>
<td>120 mmol</td>
</tr>
<tr>
<td>Potassium</td>
<td>60 mmol</td>
</tr>
<tr>
<td>Chloride</td>
<td>120 mmol</td>
</tr>
<tr>
<td>Acetate</td>
<td>50 mmol</td>
</tr>
<tr>
<td>Sulphate</td>
<td>10 mmol</td>
</tr>
<tr>
<td>Calcium</td>
<td>8.5 mmol</td>
</tr>
<tr>
<td>Magnesium</td>
<td>10 mmol</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>300 mg</td>
</tr>
<tr>
<td>Zinc</td>
<td>67 µmol</td>
</tr>
<tr>
<td>Copper</td>
<td>5 µmol</td>
</tr>
<tr>
<td>Iron</td>
<td>35 mmol</td>
</tr>
<tr>
<td>Iodine</td>
<td>1 µmol</td>
</tr>
<tr>
<td>Total volume</td>
<td>2200 ml</td>
</tr>
</tbody>
</table>

**Vitamin infusion**

Administration of folic acid was started from the initiation of TPN, in a dose of 400 µg/day (a dose of AMA-FDA formulation) in 7 cases (group A) and in a dose of 800 µg/day (a double dose of the AMA-FDA formulation) in 3 (group B). Clinical profiles of group A and B were substantially the same. Other vitamins including vitamin B1, B2, B6, B12, C, nicotinic acid, pantothenic acid, biotin, A, D, E, were given according to the AMA-FDA formulation. The vitamins in at least 500 ml of an infusion solution, shielded from the light, were administered during the night.

**Sampling**

Blood samples were obtained between 13.00 h and 15.00 h, during which time no vitamins were given, prior to TPN therapy and every week or every 2–4 weeks during TPN for 6–16 weeks with average 10.5 weeks. Blood samples were frozen immediately after sampling until the determinations for folate and other chemistry.

**Determination of folate in red cell and its normal range**

Ascorbic acid solution was mixed with 0.5 ml of whole blood, to which the 125I-pteroylglutamic acid tracer and milk folate binding protein had been added. Radioimmunoassay was then performed, using the CPBA method, using dextran (Clinical Assays Co. Cat. No. CA–521). The normal value for folate of 24 healthy controls (10 men and 14 women, mean age 27 years, range 20–38 years) was 348±98 ng/ml (mean ± s.d.; range 236–605 ng/ml).

**Results**

The folate concentration in red cell prior to the therapy was 66±38 ng/ml, being extremely low compared with a normal value (Figure 1). In group A (Cases 1–7) (400 µg/day of intravenous folic acid), red cell folate levels averaged 76 ng/ml at 8 weeks from the initiation of therapy (n = 7) and 113 ng/ml at 16 weeks (n = 3). In group B (Cases 8–10; 800 µg/day), folate levels increased with time and averaged 138 ng/ml at 6 weeks of the therapy. In a particular case (case 8) it continuously and progressively rose to a maximum of 249 ng/ml at 10 weeks.

In 9 cases, TPN led to clinical remission at 8–16 weeks of the therapy; CDAI improved from 209 to 74 on average, and radiography or endoscopy also revealed a remarkable improvement. The remaining one case (case 10) showed a poor clinical response with TPN, and underwent an operation for stricture of the ileum after 6 weeks of therapy.

In 5 cases, mild anaemia (haemoglobin concentration: 9.5–10.3 g/100ml) was evident prior to TPN therapy, but improved gradually and disappeared at 8–16 weeks of the therapy. In the remaining 5, however, haemoglobin concentration was within normal limits prior to and during TPN therapy. Megaloblastic anaemia due to folic acid deficiency was evident in none of the cases during this study period.

**Discussion**

TPN has been prescribed for patients with Crohn’s disease, the objective being to improve the nutritional state and/or to induce remission of this disease in those who fail to respond to drugs. In recent years, TPN has been used as a primary therapy for Crohn’s disease, and sustained remission has also been reported in those given long-term therapy.
Folic acid deficiency can occur in patients with Crohn's disease. Hoffbrand et al. examined 64 patients and found very low serum levels of folate in 22 patients who required hospitalization. In 5 of 7 patients for whom assay was feasible, they also found a decrease in the red cell folate concentration. Elsborg and Larsen also observed decreased serum folate levels in 35 patients with Crohn's disease and attributed this to dietary insufficiency, malabsorption, and increased cell turnover.

Although the serum folate level is commonly used as a sensitive indicator for folic acid deficiency, serum folate varies with temporary changes in the intrahepatic storage or oral intake of folic acid and is also susceptible to haemolysis at the time of blood sampling. In contrast, folate concentration in red cell is relatively independent of circumstantial factors and more accurately reflects the amount of folic acid retained in the body, thus serving as a more useful index.

In the present study, serial changes in the red cell folate were determined in patients with Crohn's disease who received folic acid of 400 μg/day (a dose of AMA-FDA formulation) or of 800 μg/day during a relatively long-term TPN. The levels of folate were far below the normal range before TPN and remained very low during an average of 10.5 weeks of TPN with daily folic acid of 400 μg. In contrast, the levels in those who received a double dose of folic acid tended to increase but never reached the normal value.

The occurrence of hypervitaminosis due to an excessive administration of folic acid is rare. Hunter et al. have reported that healthy subjects given intramuscular folic acid of 15,000 μg/day developed mental changes, sleep disturbance, and gastrointestinal symptoms. Such symptoms, however, were not documented in our cases treated with folic acid. From these findings, folic acid of more than double the dose of the AMA-FDA formulation is considered to be necessary in patients with Crohn's disease with or without long-term TPN therapy.

Acknowledgement

We thank S. Sugiyama (Central Research Laboratory, SS Pharmaceutical Co., Ltd.) for guidance with the assay of the red cell folate concentration.

References

Red cell folate concentrations in patients with Crohn's disease on parenteral nutrition.
M. Tominaga, M. Iida, K. Aoyagi, N. Kohrogi, T. Matsui and M. Fujishima

doi: 10.1136/pgmj.65.769.818

Updated information and services can be found at:
http://pmj.bmj.com/content/65/769/818

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/